Meier BC, Wagner BK. Inhibition of HDAC3 as a strategy for developing novel diabetes therapeutics. Epigenomics. 2014;6(2):209-14. doi:10.2217/epi.14.11
Vetere A, Choudhary A, Burns SM, Wagner BK. Targeting the pancreatic β-cell to treat diabetes. Nat Rev Drug Discov. 2014;13(4):278-89. doi:10.1038/nrd4231
Lundh M, Scully SS, Mandrup-Poulsen T, Wagner BK. Small-molecule inhibition of inflammatory β-cell death. Diabetes Obes Metab. 2013;15 Suppl 3:176-84. doi:10.1111/dom.12158
Schenone M, Dančík V, Wagner BK, Clemons PA. Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol. 2013;9(4):232-40. doi:10.1038/nchembio.1199
Kubicek S, Gilbert JC, Fomina-Yadlin D, et al. Chromatin-targeting small molecules cause class-specific transcriptional changes in pancreatic endocrine cells. Proc Natl Acad Sci U S A. 2012;109(14):5364-9. doi:10.1073/pnas.1201079109
Wagner BK, Gilbert TJ, Hanai J ichi, et al. A small-molecule screening strategy to identify suppressors of statin myopathy. ACS Chem Biol. 2011;6(9):900-4. doi:10.1021/cb200206w
Bochner BR, Siri M, Huang RH, et al. Assay of the multiple energy-producing pathways of mammalian cells. PLoS One. 2011;6(3):e18147. doi:10.1371/journal.pone.0018147
Kim YK, Lee JS, Bi X, et al. The binding of fluorophores to proteins depends on the cellular environment. Angew Chem Int Ed Engl. 2011;50(12):2761-3. doi:10.1002/anie.201007626
Wagner BK. Grand challenge commentary: Chemical transdifferentiation and regenerative medicine. Nat Chem Biol. 2010;6(12):877-9. doi:10.1038/nchembio.472
Cancer Target Discovery and Development Network, Schreiber SL, Shamji AF, et al. Towards patient-based cancer therapeutics. Nat Biotechnol. 2010;28(9):904-6. doi:10.1038/nbt0910-904